CD8A and neoplasm: Recent research has identified an activation state of CD11b+ DCs that can be triggered by tumor-derived IFN-I, enabling them to drive protective, systemic antitumor CD8+ T-cell immunity even in the absence of cDC1s capable of cross-presenting antigens [29].